U.S. Army Lt. Col. Nathan McWhorter, chief of Nuclear Medicine, consults with patient, Harold G. Overstreet, retired Sgt. Maj. of the Marine Corps at Brooke Army Medical Center, Fort Sam Houston, Texas, Sept. 27, 2022. Overstreet is undergoing a new treatment for prostate cancer patients which is combined with a specific type of positron emission tomography (PET) imaging agent for prostate cancer. The PET imaging allows the doctor to see where the cancer is located as well as the extent of metastasis. The new FDA-approved prostate-specific membrane antigen (PSMA) PET imaging scan significantly improves prostate cancer detection and treatment.
You are leaving Health.mil
The appearance of hyperlinks does not constitute endorsement by the Department of Defense of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.
You are leaving Health.mil
View the external links disclaimer.
Last Updated: July 18, 2024